President Donald Trump signed an executive order directing federal agencies to accelerate research and regulatory review of psychedelic substances, a move reportedly spurred by a direct text message from podcast host Joe Rogan. The order, signed during an Oval Office event, aims to fast-track the study of compounds such as ibogaine, psilocybin, and LSD for potential medical applications in mental health treatment, addiction recovery, traumatic brain injury, and PTSD.
"The text message came back: ‘Sounds great. Do you want FDA approval? Let’s do it.’" — Joe Rogan, Podcast Host
The initiative marks a significant policy shift, given that many psychedelics remain classified as Schedule I controlled substances under federal law, a category reserved for drugs with a high potential for abuse and no accepted medical use. No psychedelic drug has yet received full FDA approval in the United States, although controlled trials are ongoing for several substances.
According to reports, the impetus for the executive order came after Joe Rogan sent President Trump information regarding ibogaine, a psychoactive substance derived from a West African shrub. Ibogaine has been anecdotally used by some veterans outside the U.S. to treat trauma and opioid addiction. President Trump acknowledged Rogan's influence, stating, "We all respect Joe and he’s a little bit more liberal than I am, that’s okay. Joe is an amazing guy. He wrote me a little note about this and I had it checked out. Everybody came back with the same answer."
Rogan described President Trump's response as nearly instantaneous. "The text message came back: ‘Sounds great. Do you want FDA approval? Let’s do it,’" Rogan recounted. Within days, the administration reportedly transformed this conversation into official policy.
The executive order specifically instructs the Food and Drug Administration (FDA) to expedite the review of designated breakthrough therapies. It also calls for improved interagency data sharing and an exploration of rapid rescheduling for certain psychedelics if they receive medical approval. FDA Commissioner Marty Makary indicated that new national priority vouchers could potentially allow some qualifying drugs to move through the approval process in weeks rather than months.
President Trump framed the order primarily as a mental health initiative, with a particular focus on supporting military veterans. "In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans," President Trump stated at the signing event. To support this research, the administration plans to allocate at least $50 million in federal-state partnerships for states that establish psychedelic treatment research programs.
The substances targeted for expedited research, including psilocybin (found in "magic mushrooms"), MDMA (ecstasy), LSD, and ibogaine, are currently being studied in controlled clinical trials. Ibogaine, in particular, has garnered both interest and controversy. While supporters claim its potential benefits for PTSD, depression, addiction, and traumatic brain injury, critics point to known heart rhythm risks and more than 30 deaths that have been cited in medical literature in connection with its use. A 2024 Stanford study involving 30 veterans in Mexico reported promising results for ibogaine, though researchers acknowledged the trial's small scale and lack of a placebo group, underscoring the need for more rigorous scientific investigation.
The Oval Office signing event also drew attention due to the visible dynamic between President Trump, Joe Rogan, and Health Secretary Robert F. Kennedy Jr., with Rogan largely observed standing in the background during the ceremony. This policy move signifies a notable departure from historical federal approaches to psychedelic compounds, moving towards a more open stance on their therapeutic potential under strict research and regulatory oversight. The administration's emphasis on veteran mental health provides a clear rationale for prioritizing these experimental treatments, despite the ongoing debates surrounding their safety and efficacy. The rapid progression from an informal suggestion to a federal executive order highlights the unique channels of influence that can shape policy within the current administration.
